fbpx

Ipsen and BioLabs to open new Innovation Center in Cambridge (U.S.) to foster development of new therapies for patients

Regulatory News:

Ipsen, a global biopharmaceutical group focused on innovation and
specialty care, today announced an agreement with BioLabs to open a life
science co-working facility within Ipsen’s new North America global hub
in Kendall Square, Cambridge, Massachusetts. The shared laboratory
space, called the ‘Ipsen Innovation Center – BioLabs’ (IPSEN-ICB) will
be a fully equipped 15,000 square-feet combined office and laboratory
facility dedicated to supporting entrepreneurs and startup companies
developing the next generation of therapeutics for patients.

Ipsen Executive Vice President Research & Development, Chief
Scientific Officer, Dr. Alexandre Lebeaut, commented, “Our
focus is to address patients’ unmet medical needs, relentlessly looking
for innovative therapeutic solutions. Teaming up with BioLabs in
Cambridge today is the opportunity to create a unique innovation center
to serve this purpose.”

Ipsen is providing the space for the innovation center as well as
educational programs, mentoring and office hours with Ipsen R&D teams.
BioLabs, a national network of co-working facilities designed to help
science-based startups go further faster on limited capital investment,
is managing the operation of the facility. The space is scheduled to be
ready for occupancy in the first quarter of 2019 and BioLabs will begin
accepting applications for occupancy in the coming months. Admission to
the IPSEN-ICB will be via a competitive process.

This agreement further expands Ipsen’s footprint in Cambridge, and
follows last month’s joint announcement with the Massachusetts Life
Sciences Centre on the creation of Ipsen’s third global hub for the
company based in Cambridge. Ipsen will co-locate its North America
business with its Global External Innovation and Partnering, R&D and
Manufacturing teams, as well as certain global Commercial roles,
creating a fully integrated biopharmaceutical business in the US.

“External innovation is core to Ipsen’s growth strategy and we are
committed to supporting the biotech ecosystem that plays such a vital
role in discovering innovative new therapies,” added Ivana
Magov?evi?-Liebisch, Ph.D., J.D., EVP, Chief Business Officer. “Ipsen
is excited to partner with BioLabs to establish a world-class co-working
space that will provide a launchpad for the next generation of
high-impact biotechs.”

BioLabs Founder and CEO Johannes Fruehauf, M.D., Ph.D.,
commented, “Working with the team at Ipsen, we are proud to expand
access to state-of-the-art facilities for the scientists and
entrepreneurs in and around the Boston/Cambridge hotbed of life-science
innovation. Like all our facilities, this site will be designed to
stimulate creative interaction and collaboration with the bonus of
offering access to Ipsen’s world class R&D capabilities.”

About Ipsen

Ipsen is a global biopharmaceutical company focused on innovation and
specialty care. The group develops and commercializes innovative
medicines in three key therapeutic areas – Oncology, Neurosciences and
Rare Diseases. Its commitment to oncology is exemplified through its
growing portfolio of key therapies for prostate cancer, neuroendocrine
tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a
well-established Consumer Healthcare business. With total sales over
€1.9 billion in 2017, Ipsen sells more than 20 drugs in over 115
countries, with a direct commercial presence in more than 30 countries.
Ipsen’s R&D is focused on its innovative and differentiated
technological platforms located in the heart of the leading
biotechnological and life sciences hubs (Paris-Saclay, France; Oxford,
UK; Cambridge, US). The Group has about 5,400 employees worldwide. Ipsen
is listed in Paris (Euronext: IPN) and in the United States through a
Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For
more information on Ipsen, visit www.ipsen.com.

About BioLabs (www.biolabs.io
twitter: @bioLabsHQ)

A membership-based network of shared laboratory facilities located in
key cities with proven biotech innovation clusters, BioLabs offers
beautifully designed coworking environments that pair fully equipped and
supported lab, office, and event spaces with relevant programming and
unparalleled access to capital and industry partners. These fertile,
supportive ecosystems allow young companies to shift their focus from
startup operations to experimentation and innovation so they can reach
their scientific potential quickly and achieve business success.
Companies can start with a single lab bench and scale up as they grow.
The expanding BioLabs network now comprises sites in Boston and
Cambridge, Massachusetts; Durham, North Carolina; San Diego and San
Francisco, California; New York City, and Princeton, New Jersey.

Ipsen Forward Looking Statement

The forward-looking statements, objectives and targets contained herein
are based on the Group’s management strategy, current views and
assumptions. Such statements involve known and unknown risks and
uncertainties that may cause actual results, performance or events to
differ materially from those anticipated herein. All of the above risks
could affect the Group’s future ability to achieve its financial
targets, which were set assuming reasonable macroeconomic conditions
based on the information available today. Use of the words “believes,”
“anticipates” and “expects” and similar expressions are intended to
identify forward-looking statements, including the Group’s expectations
regarding future events, including regulatory filings and
determinations. Moreover, the targets described in this document were
prepared without taking into account external growth assumptions and
potential future acquisitions, which may alter these parameters. These
objectives are based on data and assumptions regarded as reasonable by
the Group. These targets depend on conditions or facts likely to happen
in the future, and not exclusively on historical data. Actual results
may depart significantly from these targets given the occurrence of
certain risks and uncertainties, notably the fact that a promising
product in early development phase or clinical trial may end up never
being launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. The Group must face or might face
competition from generic products that might translate into a loss of
market share. Furthermore, the Research and Development process involves
several stages each of which involves the substantial risk that the
Group may fail to achieve its objectives and be forced to abandon its
efforts with regards to a product in which it has invested significant
sums. Therefore, the Group cannot be certain that favourable results
obtained during pre-clinical trials will be confirmed subsequently
during clinical trials, or that the results of clinical trials will be
sufficient to demonstrate the safe and effective nature of the product
concerned. There can be no guarantees a product will receive the
necessary regulatory approvals or that the product will prove to be
commercially successful. If underlying assumptions prove inaccurate or
risks or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks and
uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation; global
trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new
product development, including obtaining regulatory approval; the
Group’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the
effectiveness of the Group’s patents and other protections for
innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions. The Group also depends on third
parties to develop and market some of its products which could
potentially generate substantial royalties; these partners could behave
in such ways which could cause damage to the Group’s activities and
financial results. The Group cannot be certain that its partners will
fulfil their obligations. It might be unable to obtain any benefit from
those agreements. A default by any of the Group’s partners could
generate lower revenues than expected. Such situations could have a
negative impact on the Group’s business, financial position or
performance. The Group expressly disclaims any obligation or undertaking
to update or revise any forward-looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such statements
are based, unless so required by applicable law. The Group’s business is
subject to the risk factors outlined in its registration documents filed
with the French Autorité des Marchés Financiers.

The risks and uncertainties set out are not exhaustive and the reader is
advised to refer to the Group’s 2017Registration Document available on
its website (www.ipsen.com).

View source version on businesswire.com: https://www.businesswire.com/news/home/20180718005734/en/